Tag: cardiac amyloidosis

Graph showing cardiac amyloid burden reduction and functional improvements with cliramitug therapy over 29 months
Clinical UpdatesNew StudiesPracticeResearch Digest

Monoclonal antibody cliramitug shows sustained benefit in cardiac amyloidosis over 29 months

Long-term follow-up of the NI006-101 trial shows that cliramitug, a monoclonal antibody targeting misfolded transthyretin, sustains clinical benefit in cardiac…

By
GMJ Practice Desk

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →